RecruitingNCT06448793
Patient and Physician Preference Study in Resectable, Non-small Cell Lung Cancer Treatments
Patient and Physician Preferences for Potentially Resectable, Non-metastatic Non-small Cell Lung Cancer Treatments
Sponsor
Bristol-Myers Squibb
Enrollment
55 participants
Start Date
Nov 25, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to investigate the perspectives and preferences of patients and healthcare professionals (medical oncologists, pneumologists, thoracic surgeons) regarding treatment options in the resectable non-small cell lung cancer (NSCLC) setting
Eligibility
Min Age: 18 Years
Inclusion Criteria9
- Patients
- Aged ≥18 years at the time of enrollment in the study
- Resident of the US, Germany, or Japan
- Able to read, speak, and understand English, German or Japanese
- Diagnosed with resectable phase II to IIIB non-small cell lung cancer (NSCLC)
- Physicians
- Resident of the US, Germany, or Japan
- Lung cancer-treating physician specialized in one of the following medical areas: oncology, pneumonology, thoracic surgery, or radiology
- Treated at least three new patients with resectable NSCLC in the past year
Exclusion Criteria7
- Patients
- Appears to have sensory and/or cognitive impairment(s) that could interfere with their ability to provide online and/or verbal consent, or complete any other interview activities (based on screener judgment)
- Being diagnosed with another malignancy alongside NSCLC
- Not willing to be audio-recorded during the interview
- Physicians
- Appears to have sensory and/or cognitive impairment(s) that could interfere with their ability to provide online and/or verbal consent, or complete any other interview activities (based on screener judgment)
- Not willing to be audio-recorded during the interview
Interventions
DRUGApproved Non-small Cell Lung Cancer (NSCLC) therapies
As prescribed by treating physician
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06448793
Related Trials
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
NCT072230478 locations
Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer
NCT051000691 location
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
NCT06305754156 locations
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
NCT06170788217 locations
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
NCT072881772 locations